SGMT News
Archived Headlines
- Biotechs Apogee and Sagimet slated to kick off the July IPO market 07/11/23
- Liver disease and cancer biotech Sagimet Biosciences sets terms for $75 million IPO 07/10/23
- US IPO Week Ahead: Surf Air Mobility slated to complete the first direct listing of 2023 07/07/23
- US IPO Weekly Recap: The summer calendar starts to fill up 06/23/23
- Liver disease and cancer biotech Sagimet Biosciences refiles for a $75 million IPO 06/23/23
Updated: Renaissance Capital's 3Q 2023 US IPO Market Review
Large Tech IPOs Stage a Comeback in a Volatile 3Q The third quarter of 2023 produced 30 IPOs that raised a combined $7.8 billion, more than the proceeds raised in the full-year 2022 despite no...read more
Renaissance Capital's July IPO Market Update
Eleven issuers raised a combined $939 million in July, well below the 10-year average (22 IPOs, $5.1B). Four deals raised $80 million or more, along with the year’s first direct listing (SRFM), and a wave of small issuers, which have largely disappeared...read more
US IPO Weekly Recap: July IPO market kicks off with sizable biotechs
Following the Independence Day lull, the July IPO market warmed up with two sizable biotechs, joined by two blank check...read more
Liver disease and cancer biotech Sagimet Biosciences prices upsized IPO at $16 midpoint
Sagimet Biosciences, a Phase 2 biotech developing a selective FASN inhibitor for NASH and cancers, raised $85 million by offering 5.3 million shares at $16, within the range of $15 to $17. The company offered 0.6 million more shares than anticipated. Sagimet...read more